What to watch. Vivimed Labs: Gets Nil observation from USFDA

Vivimed Laboratories on Tuesday said the US health regulator had recently inspected the drug maker’s manufacturing plant in Spain and has not issued any observations. In a notice to the exchanges, the drug firm said its active pharmaceutical ingredient manufacturing facility at Sant Celoni, Spain, was recently inspected by the USFDA. At the end of the successful inspection, ‘zero’ 483 observations were issued, it added. Shares may react positively.